20 Oct 2023 Research
Emerging leaders accolade for former Leukaemia UK John Goldman Fellows
Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major scientific journal, Leukemia. The Nature Publishing Group journal’s Emerging Leaders collection recognises new, ground-breaking researchers in the haematology field.
This prominent recognition for two of Leukaemia UK’s former John Goldman Fellows, comes in the same week that we announce £600,000 funding for four new Fellows, each seeking to find kinder, more effective treatments for acute myeloid leukaemia (AML).
Our prestigious John Goldman Fellowships are aimed at early career researchers with a passion for science and a desire to develop new ideas and translate scientific advances into clinical practice. The fellowships aim to support and empower the scientific leaders of the future.
Dr Matthew Blunt was awarded a Leukaemia UK John Goldman Fellowship in 2019. Through his work he has found new ways to direct immune cells called natural killer cells against leukaemia – discoveries which could lead to effective treatments with fewer side effects, to save more lives. Dr Blunt and his team are now focusing on the best way to overcome resistance to the immune system in leukaemia and aim to evaluate this in a future clinical trial.
In 2020, Dr Konstantinos Tzelepis was awarded a Leukaemia UK John Goldman Fellowship to investigate the METTL3 protein, and its role in how AML cells develop. Dr Tzelepis identified a new targeted drug with the potential to treat the disease. Now, Dr Tzelepis and his colleagues at STORM therapeutics are continuing to develop the potential drug, which is being tested in a Phase 1 US-based clinical trial for patients with aggressive malignancies. Safety results from this study will inform future trials, which could include AML patients.
This year, Dr Tzelepis, was awarded £250,000 as part of Leukaemia UK’s inaugural John Goldman Fellowship Follow-up Fund award. The fund is a further commitment to the UK’s future blood cancer research leaders, seeking to advance our understanding and ability to treat leukaemia and other blood cancers.
11 August 2021
Dr Samanta Mariani recognised for her innovative research through Leukaemia UK John Goldman Fellowship and Olive Boles Innovation Award
We are delighted to announce the Leukaemia UK John Goldman Fellowship and Olive Boles Innovation Award has been awarded to Dr Samanta Mariani, in recognition of her innovative research that could contribute significantly to our understanding of leukaemia and other blood cancers.
10 January 2023
Clinical trial begins for pioneering new cancer treatment
Dr Konstantinos Tzelepis was awarded a Leukaemia UK research fellowship in 2020 and has developed a new class of cancer drug with the potential to treat leukaemia.
17 October 2023
Leukaemia UK announces four pioneering projects into one of the deadliest forms of cancer
Applications for the 2024 John Goldman Fellowships will open on 01 December 2023. The deadline for applications is 12 noon on 31 January 2024. Find out more and apply. Leukaemia UK…
31 August 2023
“Henry’s death cannot have been for nothing” says bereaved Mum as charities fund new research into devastating infant leukaemia
Callan Brett, a mother-of-two from Ipswich, has welcomed news of a pioneering new research project into infant leukaemia; having lost her youngest son to the rare form of blood cancer…